Levodropropizine

Last updated
Levodropropizine
Levodropropizine.svg
Clinical data
AHFS/Drugs.com International Drug Names
ATC code
Pharmacokinetic data
Protein binding 11-14%
Excretion 83% via urine within 96 h
Identifiers
  • (2S)-3-(4-phenylpiperazin-1-yl)propane-1,2-diol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
ECHA InfoCard 100.167.719 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C13H20N2O2
Molar mass 236.315 g·mol−1
3D model (JSmol)
  • O[C@@H](CN2CCN(c1ccccc1)CC2)CO
  • InChI=1S/C13H20N2O2/c16-11-13(17)10-14-6-8-15(9-7-14)12-4-2-1-3-5-12/h1-5,13,16-17H,6-11H2/t13-/m0/s1 Yes check.svgY
  • Key:PTVWPYVOOKLBCG-ZDUSSCGKSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Levodropropizine is a cough suppressant. It is the levo isomer of dropropizine. It acts as a peripheral antitussive, with no action in the central nervous system. [1] It does not cause side effects such as constipation or respiratory depression which can be produced by opioid antitussives such as codeine and its derivatives.

Levopront Levodropropizine Levopront3.jpg
Levopront

In September 2021, Korea United Pharm file lawsuits against 15 drug manufacturers as patent infringement protection for its 2017 registered antitussive drug Levotics CR Tab. (levodropropizine). The cases are anchored on violation of its patent for "Method for Preparing Sustained-Release Tablets Containing Levodropropizine." [2] In September 2023, KUP signed a five-year $52.1 million contract with MCQ, a Thai-based pharmaceutical company, for supply of its mucoactive drug, Levotics CR Tab (levodropropizine). [3]

Related Research Articles

<span class="mw-page-title-main">Recreational use of dextromethorphan</span> Cough suppressant drug susceptible to misuse.

Dextromethorphan, or DXM, a common active ingredient found in many over-the-counter cough suppressant cold medicines, is used as a recreational drug and entheogen for its dissociative effects. Street names include Brownies, Dextro, Drix, Gel, Groove, Lean, Mega-perls, Poor man's ecstasy, Red devils, Robo, Rojo, Rome, Skittles, Sizzurp, Sky and Velvet.

<span class="mw-page-title-main">Cold medicine</span> Medication taken to relieve cold symptoms

Cold medicines are a group of medications taken individually or in combination as a treatment for the symptoms of the common cold and similar conditions of the upper respiratory tract. The term encompasses a broad array of drugs, including analgesics, antihistamines and decongestants, among many others. It also includes drugs which are marketed as cough suppressants or antitussives, but their effectiveness in reducing cough symptoms is unclear or minimal.

<span class="mw-page-title-main">Guaifenesin</span> Expectorant medication

Guaifenesin, also known as glyceryl guaiacolate, is an expectorant medication taken by mouth and marketed as an aid to eliminate sputum from the respiratory tract. Chemically, it is an ether of guaiacol and glycerine. It may be used in combination with other medications. A 2014 study found that guaifenesin has no effect on sputum production or clearance in upper respiratory infections.

<span class="mw-page-title-main">Dextrorphan</span> Psychoactive cough suppressant medication

Dextrorphan (DXO) is a psychoactive drug of the morphinan class which acts as an antitussive or cough suppressant and in high doses a dissociative hallucinogen. It is the dextrorotatory enantiomer of racemorphan; the levorotatory enantiomer is levorphanol. Dextrorphan is produced by O-demethylation of dextromethorphan by CYP2D6. Dextrorphan is an NMDA antagonist and contributes to the psychoactive effects of dextromethorphan.

Benzonatate, sold under the brand name Tessalon among others, is a medication that is used for the symptomatic relief of cough. A 2023 systematic review found that there is inadequate evidence to support the effectiveness and safety of benzonatate for cough and highlighted rising safety concerns. Benzonatate is taken by mouth. Effects generally begin within 20 minutes and last 3 to 8 hours.

<span class="mw-page-title-main">Dextromethorphan</span> Cough suppressant, antidepressant, and dissociative drug

Dextromethorphan (DXM), sold under the trade name Robitussin among others, is a cough suppressant used in many cough and cold medicines. It affects serotonin, norepinephrine, NMDA, and sigma-1 receptors in the brain, all of which have been implicated in the pathophysiology of depression. In 2022, the FDA approved the combination dextromethorphan/bupropion to serve as a rapid acting antidepressant in patients with major depressive disorder.

<span class="mw-page-title-main">Halls (cough drop)</span> Cough drops brand

Halls is a British brand of a mentholated cough drop owned by Mondelēz International since 2015. In 2016, it was one of the biggest selling brands of over-the-counter medications sold in Great Britain, with sales of £32.5 million.

Mucoactive agents are a class of chemical agents that aid in the clearance of mucus or sputum from the upper and lower airways, including the lungs, bronchi, and trachea. Mucoactive drugs include expectorants, mucolytics, mucoregulators, and mucokinetics. These medications are used in the treatment of respiratory diseases that are complicated by the oversecretion or inspissation of mucus. These drugs can be further categorized by their mechanism of action.

<span class="mw-page-title-main">Pholcodine</span> Chemical compound

Pholcodine is an opioid cough suppressant (antitussive). It helps suppress unproductive coughs and also has a mild sedative effect, but has little or no analgesic effects. It is also known as morpholinylethylmorphine and homocodeine.

<span class="mw-page-title-main">Pentoxyverine</span> Antitussive / cough suppressant

Pentoxyverine (rINN) or carbetapentane is an antitussive commonly used for cough associated with illnesses like common cold. It is sold over-the-counter as Solotuss, or in combination with other medications, especially decongestants. One such product is Certuss, a combination of guaifenesin and pentoxyverine. The drug has been available in the form of drops, suspensions and suppositories.

<span class="mw-page-title-main">Clofedanol</span> Chemical compound

Clofedanol (INN) or chlophedianol (BAN), sold under multiple different brand names, is a centrally acting cough suppressant used in the treatment of dry cough. Clofedanol has local anesthetic, antispasmodic, and antihistamine properties, and may have anticholinergic effects at high doses.

<span class="mw-page-title-main">Dimethoxanate</span> Chemical compound

Dimethoxanate is a cough suppressant of the phenothiazine class.

<span class="mw-page-title-main">Cloperastine</span> Chemical compound

Cloperastine (INN) or cloperastin, in the forms of cloperastine hydrochloride (JAN) and cloperastine fendizoate, is an antitussive and antihistamine that is marketed as a cough suppressant in Japan, Hong Kong, and in some European countries. It was first introduced in 1972 in Japan, and then in Italy in 1981.

<span class="mw-page-title-main">Zipeprol</span> Cough suppressant drug

Zipeprol is a centrally acting cough suppressant developed in France in the 1970s. It is not a morphinan derivative. Zipeprol acts as a local anaesthetic and has mucolytic, antihistamine and anticholinergic properties. It is sold with several brand names such as Zinolta and Respilene. It is not available in the United States or Canada and has been discontinued in Europe. It is still available in some countries in Asia and South America.

<span class="mw-page-title-main">Butamirate</span> Cough suppressant

Butamirate is a cough suppressant. It has been marketed in Europe and Mexico, but not in the United States.

<span class="mw-page-title-main">Benproperine</span> Chemical compound

Benproperine (INN) is a cough suppressant. It has been marketed in multiple countries in Central America and Europe, as the phosphate or pamoate salts in either tablet, dragée, or syrup form. Trade names include Blascorid in Italy and Sweden, Pectipront and Tussafug in Germany, and Pirexyl in Scandinavia. The recommended dosage for adults is 25 to 50 mg two to four times daily, and for children 25 mg once or twice daily. Adverse effects include dry mouth, dizziness, fatigue, and heartburn.

<span class="mw-page-title-main">Dimemorfan</span> Cough suppressant

Dimemorfan (INN), or dimemorfan phosphate (JAN), also known as 3,17-dimethylmorphinan, is an antitussive of the morphinan family that is widely used in Japan and is also marketed in Spain and Italy. It was developed by Yamanouchi Pharmaceutical and introduced in Japan in 1975. It was later introduced in Spain in 1981 and Japan in 1985.

<span class="mw-page-title-main">Samsung Biologics</span> South Korean biotechnology company

Samsung Biologics Co., Ltd. is a global contract development and manufacturing organization headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, its core services range from late discovery to large-scale commercial manufacturing. The company focuses on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and mRNA vaccines.

<span class="mw-page-title-main">Hanmi Pharm</span> South Korean pharmaceutical company

Hanmi Pharm Co., Ltd. is a South Korean pharmaceutical company that is headquartered in Seoul.

<span class="mw-page-title-main">Moguisteine</span> Chemical compound

Moguisteine is a non-narcotic, peripherally acting antitussive. In a small double-blind, randomized controlled trial, 200 mg of moguisteine suspension taken 3 times daily significantly reduced the frequency of coughing in patients with COPD, compared to placebo. It has also been studied in small trials in comparison to codeine and dextromethorphan, and has similar efficacy to both. It has not been approved for use in the United States.

References

  1. De Blasio F, Dicpinigaitis PV, Rubin BK, De Danieli G, Lanata L, Zanasi A (January 2012). "An observational study on cough in children: epidemiology, impact on quality of sleep and treatment outcome". Cough. 8 (1): 1. doi: 10.1186/1745-9974-8-1 . PMC   3274450 . PMID   22269875.
  2. Chan-hyuk, Kim (September 9, 2021). "Korea United Pharm sues 15 drugmakers to protect cough suppressant's patent". Korea Biomedical Review . Retrieved July 29, 2024.
  3. "Korea United Pharm to supply mucoactive drugs worth $52 million to Thailand". Korea Biomedical Review. September 9, 2023. Retrieved July 29, 2024.